Patient Power: How Do the Latest Myeloma Treatment Approvals Affect Newly Diagnosed Patients?

Last year, multiple myeloma experienced unprecedented progress, as four new drugs were approved. You can read about that at Holiday Blessings for Myeloma Patients? Now More Than Ever! and Washington Post: For Multiple Myeloma Community, a November to Remember. For the newly-diagnosed patient, what do these new treatment options mean for them? Does one's transplant options matter anymore? For Patient Power, myeloma patient and advocate, Jack Aiello, asked multiple myeloma experts John Burke, MD and Faith Davies, MD, MBBCh, MRCP, FRCPath. You can watch the interview here:

... [if patients] do have a transplant as part of that initial therapy, if [they're] young enough or fit enough to be able to tolerate that, that the response to the therapy is much improved and that that, again, translates to a better outcome. And importantly, they did some very, I can say, sensitive and posh testing to see how low and how little myeloma they could find in these patients.  And they could see that in some patients, they couldn’t detect any myeloma, even at a level of looking for one myeloma cell in a million normal cells.

To read the entire transcript, click here.